• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

PRDM6 Polyklonaler Antikörper

PRDM6 Polyklonal Antikörper für WB, Indirect ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, Indirect ELISA

Konjugation

Unkonjugiert

Kat-Nr. : 33205-1-PBS

Synonyme

EC:2.1.1.361, PFM3, PR domain zinc finger protein 6, PR domain-containing protein 6, Putative histone-lysine N-methyltransferase PRDM6

Filter:
  • Western Blot (WB) analysis of various lysates using PRDM6 Polyclonal antibody (33205-1-AP)

    WB analysis using 33205-1-AP (same clone as 33205-1-PBS)

    Various lysates were subjected to SDS PAGE followed by western blot with 33205-1-AP (PRDM6 antibody) at dilution of 1:3000 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 33205-1-PBS in a different storage buffer formulation.

Geprüfte Anwendungen

Produktinformation

33205-1-PBS bindet in WB, Indirect ELISA PRDM6 und zeigt Reaktivität mit human

Getestete Reaktivität human
Wirt / Isotyp Kaninchen / IgG
Klonalität Polyklonal
Typ Antikörper
Immunogen PRDM6 fusion protein Ag38054
Vollständiger Name PR domain containing 6
Berechnetes Molekulargewicht595aa, 64 kDa
Beobachtetes Molekulargewicht75 kDa
GenBank-ZugangsnummerNM_001136239
Gene symbol PRDM6
Gene ID (NCBI) 93166
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Antigen-Affinitätsreinigung
Lagerungspuffer PBS only
LagerungsbedingungenStore at -80°C. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

PRDM6 is a poorly characterized member of the PRDF1 and RIZ1 homology domain-containing (PRDM) family of transcription factors that possess histone lysine methyltransferase activities through their catalytic SET domain. Based on findings in other species, PRDM6 is currently classified as a pseudo-methyltransferase that may interact with the methyltransferase G9a and corepressors to indirectly affect the methylation status of histone H3 lysine and histone H4 lysine. PRDM6 inhibition may have therapeutic value in PRDM6-expressing medulloblastomas (PMID: 38992221). PRDM6 has one glycosylation modification site.